BR Ventures (BRV) is Cornell's student-run venture capital fund, providing a vital connection between intellectual properties and needed financial resources by infusing venture capital and business expertise into promising Cornell and local startups. The Fund provides seed capital, typically ranging between $50,000 and $200,000, to selected businesses. Over its lifetime, BRV will invest up to $10,000,000 in business entities, most of which will be sourced through the extended Cornell community. BRV is funded by donations to the University and returns are used to create a growing pool of investment capital and build the endowment.  The Fund has undertaken several initiatives to facilitate the commercialization of Cornell technology and to expand the scope of entrepreneurship throughout the extended Cornell community. These initiatives include the $25,000 Cornell Venture Challenge, partnering with Cornell's technology transfer office-CCTEC, participation in the Cornell Entrepreneurship and Venture Capital Club's annual symposium, working to build a strong relationship with Entrepreneurship@Cornell, and developing an extensive network among alumni. BRV has also developed informal relationships with a number of unaffiliated later stage venture capital firms and incubators.

Big Red Ventures

Kleiner Perkins is a venture capital firm specializing in investing in early-stage, growth, and incubation companies. The firm continues that legacy, investing in founders with bold ideas that span industries and continents, partnering with them from inception to IPO and beyond to maximize the potential of their ideas. They also focus on early computer firms using their devices and programming and service companies. It also invests in the digital, life sciences, and healthcare industries.

Kleiner Perkins

Sutter Hill Ventures has financed technology-based start-ups and assisted entrepreneurs in building companies since 1962. Through their decades of experience, they have developed strong industry networks, considerable operating and venture capital experience, and an understanding of the challenges that early-stage and high-growth companies face. They offer expertise in developing business strategies and partnerships, building management teams, and financing companies in both public and private markets. They have experienced operating executives who love building companies. Their approach is straightforward. They have a collegial and uncomplicated operating style that is direct and results-driven. They work as a team to respond quickly to new investment proposals and to their portfolio companies needs. Once they invest in a company, they bring to bear their time, expertise, and extensive industry networks to help these companies succeed. Building companies is their top priority and their favorite occupation. They have structured Sutter Hill to allow them to invest in a focused portfolio of early-stage companies and build value for the long term. They are always available to their CEOs and founders as advisors and mentors ready with practical and strategic advice from their own venture capital and operating experiences. They don't insist on winning every argument, but they will always tell you what they think. They also have a network of executives, advisors, and support infrastructure to help their portfolio get going in the right direction quickly. As former line managers themselves, they know the vision, energy, and commitment that building a successful company requires. They strive to build partnerships with entrepreneurs that combine dedicated support from Sutter Hill with trust that the teams they back can make good decisions and execute on the details. Their limited partners have committed long-term support to their evergreen fund which allows them to make long-term commitments to their companies. In addition, a significant portion of every dollar they invest in their own money, and each one of them participates in every investment. This direct investment reinforces each partner's commitment to every company in their portfolio and ensures that they bring every available resource to bear in helping their companies succeed.

Sutter Hill Ventures

Alloy Ventures is an early stage venture capital firm that invests in the areas of life sciences, information technology, and cleantech.

Alloy Ventures

[AllianceBernstein](http://www.alliancebernstein.com) is a publicly traded global asset management firm, with approximately $735 billion in assets under management at March 31, 2008.

AllianceBernstein

Maverick Ventures is the venture arm of multi-billion dollar investment firm Maverick Capital. Combining the resources of a global firm with the benefits of an agile, focused team, Maverick Ventures supports entrepreneurs from seed through maturity. With over 30 years of early-stage investment experience, the Maverick Ventures team has funded more than 100 companies in the healthcare, software and deep technology sectors. The highly-experienced team of operating executives and investors at Maverick Ventures generally lead rounds, take board seats and work with management to build successful enterprises.

Maverick Ventures

The DAG (Duff Ackerman & Goodrich) Ventures partnership began with investments in the cable TV, infrastructure, media, and wireless industries in the 1980's. The firm now invests in a variety of technology companies.

DAG Ventures

Morgan Stanley, from the number of their offices and employees to the experience of their management and the quality of their financial results, the facts about Morgan Stanley tell an impressive story.  Morgan Stanley and its people have helped redefine the meaning of financial services. The firm has continually broken new ground in advising its clients on strategic transactions, pioneering the global expansion of finance and capital markets, and providing new opportunities for individual and institutional investors.  Morgan Stanley maintained comprehensive corporate governance guidelines for years before corporate governance became headline news.

Morgan Stanley

T. Rowe Price is an investment management firm dedicated to funding technology startups. The firm serves individuals, financial intermediaries, and institutions and offers a full range of investment strategies across a broad spectrum: debt, equities, and private equities.

T. Rowe Price

Intel Capital invests in innovative startups targeting cloud and AI infrastructure, edge, 5G, autonomy, cybersecurity, client & gaming, enterprise applications, silicon design and manufacturing, and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested US$12.9 billion in more than 1,582 companies worldwide. Intel Capital has adopted the Diversity Term Sheet Rider.

Intel Capital

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Wellcome Trust

Monsanto specializes in providing agricultural products. Their agricultural products are intended to help farmers grow crops while using energy, water, and land. They also provide seeds, traits, software, and crop protection products, thereby helping farmers improve yield.

Monsanto

Ontario Teachers' Pension Plan invests and administers the pensions of active and retired teachers. It invests the pension fund's assets and administers the pensions of 284,000 active and retired teachers in Ontario. A pension plan has existed for Ontario teachers since 1917. Today, the plan's members include 173,000 teachers in elementary and secondary schools in Ontario, 111,000 pensioners, and 72,000 inactive members. The plan has one of Canada's largest payrolls with $4.2 billion in benefits paid to plan members and $2.3 billion received in total contributions from teachers and the provincial government in 2008.

Ontario Teachers' Pension Plan

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

Deerfield

For 30 years the _Mohr Davidow Ventures team has invested in early stage technology-based startups that redefine or create large new markets. They believe that emerging information technology innovations are enabling a decade-long opportunity to invest in the “Era of Digital Engagement,” one in which personal, commercial, and public sector interactions of all kinds will be profoundly reengineered to leverage the power of mobile devices, cloud computing, and data analytics.  The Firm seeks to identify and partner with exceptional entrepreneurs who leverage these technologies to build companies where seamless, deep engagement with customers will create billion dollar markets in a number of different verticals. These verticals include: Digital Marketing, Advertising, & Media, Collaborative Enterprise Applications, The Digitization of Education and Health, Digital Financial Services, E‐commerce & Digital Retail Innovation, Mobile/Web‐Powered “LifeTech.” The Firm also has previous investments in the innovative life sciences & genomics space.  Leading companies funded by Mohr Davidow Ventures includes: Agile (Acquired by NYSE: ORCL); Aryaka Networks; Brocade; Coupa; Genomatica; HealthTap; Infusionsoft; Kabbage; nLight; ONI Systems (Acquired by NASDAQ: CIEN); Proofpoint (NASDAQ: PFPT); Rally Software (NYSE: RALY); Rocket Fuel (NASDAQ: FUEL); Rambus; Shutterfly (NASDAQ: SFLY); Ticketfly; Verinata Health (Acquired by NASDAQ: ILMN); and Visible Measures. The Firm has $1.85 billion under management.

Mohr Davidow Ventures

Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company markets and sells its clinical diagnostic products in the United States directly and outside the United States primarily through distributors, as well as through its direct sales force, and the company also markets and sells its other products through collaborative partners. The company's blood screening products are marketed and distributed worldwide by Novartis. In addition, the company has agreements with Siemens (as assignee of Bayer Corporation), bioMÃ©rieux, Inc., or bioMÃ©rieux, and Fujirebio, Inc., through its subsidiary Rebio Gen, Inc., or Rebio Gen, to market products in various overseas markets. The company is developing NAT assays and instruments for the detection of harmful pathogens in the environment and biopharmaceutical and beverage manufacturing processes. The company has entered into collaboration agreements with GE Infrastructure Water and Process Technologies, or GEI, a unit of General Electric Company, and Millipore Corporation, or Millipore, under which the company would be primarily responsible for developing and manufacturing assays for exclusive use or sale by its collaborative partners in specified fields with in the industrial testing market. Products The company has applied its core technologies to develop multiple product lines, all of which utilize its expertise in NAT probes, sample collection and processing. The company categorizes its products into clinical diagnostic products and blood screening products. Clinical Diagnostic Products Within its clinical diagnostic product group, the company has developed products for the detection of non-viral and viral microorganisms and for the detection of markers for cancer. Clinical Diagnostic Products for the Detection of Non-Viral Microorganisms The company has developed FDA-approved amplified and non-amplified NAT assays that detect non-viral micro-organisms primarily for use in clinical diagnostics. The company's principal products for the detection of non-viral microorganisms include its non-amplified AccuProbe and PACE family of products and its amplified Mycobacterium Tuberculosis Direct Test and amplified APTIMA products. AccuProbe Products: The company's AccuProbe Culture Identification products are tools for the identification of mycobacterial, fungal and bacterial pathogens, with sensitivities and specificities approaching 100% in most cases. These products allow for the detection of target organisms from primary cultures, eliminating the additional labor of purifying secondary cultures. All AccuProbe Culture Identification assays are based on its HPA technology. As part of its AccuProbe Culture Identification product line, the company also has developed a procedure to detect GBS from broth culture. Group A Streptococcus Direct: The Group A Streptococcus Direct Test, or GASDirect assay, is a NAT assay for the direct detection of Streptococcus pyogenes in one hour from a throat swab. PACE Product Family: The company's PACE 2C offers the testing for both chlamydia infections and gonorrhea from a single patient specimen.

Gen-Probe

Deerfield Capital Management (''DCM'') is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1993.

Deerfield Capital Management

Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.

Redmile Group

PacBio

PacBio designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.

PacBio

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless